The effect of exogenous glucose-dependent insulinotropic polypeptide in combination with glucagon-like peptide-1 on glycemia in the critically ill

What Was Tested

This randomized controlled trial paper looks at GIP (Gastric Inhibitory Polypeptide).

Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) have additive insulinotropic effects when coadministered in health.

The researchers aimed to determine whether GIP confers additional glucose lowering to that of GLP-1 in the critically ill.

Who Took Part

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and crossover study.

The participants were allocated by chance, so the GIP (Gastric Inhibitory Polypeptide) group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on GIP (Gastric Inhibitory Polypeptide), so expectations could not easily colour the readings.

In the crossover set-up each of the participants took both GIP (Gastric Inhibitory Polypeptide) and the comparison in turn, acting as their own control.

Between T60 and T420 minutes, nutrient liquid was infused into the small intestine at 1.5 kcal/min.

What Was Measured

PubMed files the paper under topics including Blood Glucose, Critical Illness, Gastric Inhibitory Polypeptide, Glucagon-Like Peptide 1 and Hyperglycemia.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of GIP (Gastric Inhibitory Polypeptide).

The abstract goes on to report its results in about 3 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2013 (Diabetes care), a journal based in United States.

More context: the GIP (Gastric Inhibitory Polypeptide) compound page, all human trials.